Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod versus hydroxychloroquine plus prednisone for active primary Sjogren's syndrome
ChiCTR1900022696Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of iguratimod in Sjögren's syndrome (SS) (2 arms), sponsored by Tongji Hospital. Primary endpoints: ESSDAI score, Serum IgG and 4 more. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
iguratimod
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on ChiCTR1900022696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022696.